1. What Is the Crohn Disease Market?
The Crohn Disease Market covers the biologics and the targeted synthetic immunomodulators used to treat the transmural granulomatous inflammation that can affect any segment from the mouth to the anus. The approximately 3 million Crohn's disease patients in the United States and Europe carry the inflammation. The ileocolonic involvement is most common. The penetrating, the stricturing, and the inflammatory phenotypes each require the distinct medical and surgical management. Crohn's disease biologic treatment uses the anti-TNF agents infliximab, adalimumab, and certolizumab pegol as the first-line biologic and the anti-integrin vedolizumab for the gut-selective mechanism that avoids the systemic immunosuppression. The anti-IL-12/23 ustekinumab, the anti-IL-23 risankizumab, and the JAK inhibitor upadacitinib treat the moderate-to-severe Crohn's disease that the TNF inhibitor monotherapy cannot maintain in remission. The Crohn's disease market is advancing with the risankizumab ADVANCE and MOTIVATE Phase III trials demonstrating the superior clinical remission and the endoscopic response versus placebo in the TNFi-experienced Crohn's disease patients. The SEQUENCE trial demonstrated the head-to-head superiority over ustekinumab at week 24.
2. Crohn Disease Market Size & Forecast
3. Emerging Technologies
- Risankizumab Skyrizi ADVANCE and MOTIVATE Phase III induction trials demonstrated 45 and 42 percent clinical remission at week 12 versus placebo 22 and 19 percent. The FORTIFY maintenance trial showed 52 percent clinical remission at week 52 with the endoscopic response of 47 percent in the TNFi-naive and TNFi-experienced Crohn's disease patients. The trials establish the IL-23 p19 selective mechanism. The mechanism is the effective second-line biologic after TNFi. The TNFi-experienced patient benefits from the IL-23 selective inhibition.
- Upadacitinib CELEST and U-EXCEED Phase III Crohn's disease demonstrated the 39 percent clinical remission at week 12 in the CELEST and the 49 percent endoscopic remission at week 52 in the U-EXCEED. The trials provide the oral JAK1 inhibitor. The moderate-to-severe Crohn's disease patient who has failed the TNF inhibitor benefits from the JAK1 inhibitor. The patient who prefers the oral targeted therapy to the biologic injection selects the upadacitinib.
- Vedolizumab GEMINI 2 and 3 Phase III Crohn's disease demonstrated the 14.5 percent clinical remission at week 6 that the gut-selective anti-integrin achieves for the induction at a lower rate than the anti-TNF. The 39 percent clinical remission at week 52 provides the gut-selective mechanism. The maintenance achieves the 39 percent remission. The patient with the prior opportunistic infection or the malignancy benefits from the gut-selective immunosuppression avoidance.
- Top-down biologic therapy approach uses the biologic as the first-line treatment in the newly diagnosed high-risk Crohn's disease patient. The patient has the extensive disease, the deep ulceration, the perianal disease, or the prior resection. The approach demonstrates the superior mucosal healing. The early aggressive treatment precedes the conventional therapy failure that the step-up approach requires. The early treatment achieves the hospitalisation reduction.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Inflammatory Bowel Disease Market.
4. Key Market Opportunity
Material revenue potential in the Crohn Disease market is IL-23p19 inhibitor expansion in Crohn's, where the recently approved risankizumab and mirikizumab IL-23p19 inhibitors expand biologic mechanism options. AbbVie and Eli Lilly capture this growing IL-23p19 Crohn's market. Adjacent demand centers on biosimilar TNF and vedolizumab expansion. As IL-23p19 Crohn's adoption proceeds and biosimilar access grows, the addressable opportunity is evolving from TNF-dominant Crohn's treatment toward multi-mechanism biologic Crohn's therapy.
5. Top Companies in the Crohn Disease Market
The following organisations hold leading positions in the Crohn Disease Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- AbbVie
- Johnson and Johnson
- Takeda
- Pfizer
- Eli Lilly
- Bristol-Myers Squibb
- Roche
- Boehringer Ingelheim
- Celltrion
- Samsung
- UCB
- Roivant Sciences
6. Market Segmentation
The Crohn Disease Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | TNF InhibitorAnti-IntegrinAnti-IL-12/23IL-23p19JAK Inhibitor |
| By Setting | Moderate-Severe ActiveMaintenanceTreatment-Resistant |
| By Drug | AdalimumabInfliximabVedolizumabUstekinumabRisankizumabUpadacitinib |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Crohn Disease Market trajectory over the forecast period:
Risankizumab ADVANCE and MOTIVATE Phase III 45 and 42 Percent Clinical Remission Versus 22 and 19 Percent Placebo With SEQUENCE Head-to-Head Superiority Over Ustekinumab Has Established the IL-23 Selective Inhibitor as the Superior Second-Line Crohn's Disease Biologic After TNFi Failure.AbbVie's risankizumab ADVANCE and MOTIVATE induction trials demonstrated 40-45% endoscopic response at 12 weeks in moderate-to-severe Crohn, a benchmark that exceeds the 25-35% endoscopic response rates from anti-TNF, anti-integrin, and anti-IL-12/23 trials conducted in similar populations. The maintenance FORTIFY trial demonstrated sustained clinical remission of 52% and endoscopic remission of 46.5% at 52 weeks, establishing that risankizumab induction responders maintain benefit at rates consistent with the highest-performing agents in any IBD indication. The superior endoscopic outcomes in Crohn disease for risankizumab versus historical benchmarks have moved endoscopic remission rather than clinical remission to the primary endpoint standard in CD biologic development programmes, raising the regulatory bar that future CD treatments must clear.
Upadacitinib U-EXCEED Phase III 49 Percent Endoscopic Remission at Week 52 in Biologic-Failed Crohn's Disease Has Established the Oral JAK1 Inhibitor as the Effective Alternative to Biologic Injection for the Moderate-to-Severe Crohn's Patient Who Has Failed TNF Inhibitor.AbbVie's upadacitinib U-EXCEED trial demonstrated 49% clinical remission at 12 weeks in biologic-naive Crohn patients, with clinical remission evident by week 4 in a meaningful proportion of patients who respond quickly to the oral JAK1 inhibitor mechanism. The rapid onset of upadacitinib clinical benefit within 2-4 weeks compared with the 6-10-week onset typical of subcutaneous or intravenous biologic induction enables earlier treatment assessment and pivot to alternative therapy for non-responders that reduces the duration of uncontrolled disease activity during the induction period. The oral once-daily tablet administration of upadacitinib addresses the substantial population of Crohn disease patients who prefer oral therapy, and the combination of rapid onset and oral route creates a commercial positioning complementary to the slow-onset but highly durable subcutaneous and intravenous biologics.
Vedolizumab GEMINI 2 Gut-Selective Anti-Integrin 39 Percent Week 52 Clinical Remission With Systemic Immunosuppression Avoidance Has Established the Gut-Restricted Mechanism as the Preferred Crohn's Biologic for the Patient With Prior Opportunistic Infection or Malignancy Contraindication to Systemic Biologics.The COMBINATION trial pairing vedolizumab anti-integrin with adalimumab anti-TNF and the EXPLORER trial pairing risankizumab with upadacitinib are testing the hypothesis that complementary mechanism combination can achieve higher endoscopic remission rates than optimised single-agent biologic induction in patients with moderate-to-severe refractory Crohn disease. The scientific rationale for combination therapy involves targeting both the peripheral immune activation through TNF and T-cell trafficking blockade simultaneously with TNF inhibition plus vedolizumab, or blocking the upstream IL-23 driver while simultaneously suppressing downstream JAK-mediated cytokine signalling through risankizumab plus upadacitinib combination. Payer resistance to combination biologic prescribing based on drug acquisition cost requires demonstration of superior efficacy that justifies cost before commercial adoption occurs, and Phase 3 combination trial data are the prerequisite for guideline endorsement and payer coverage of the combination approach.
For related market intelligence, see the Ulcerative Colitis Market.
8. Segmental Analysis
By drug class, the tumour necrosis factor inhibitor segment dominated the Crohn Disease Market in 2025, as established agents and biosimilars from AbbVie and Johnson and Johnson anchored treatment across the patient population, generating the largest share of Crohn disease revenue.
By setting, the biologic-experienced segment is projected to register the highest growth rate through 2034, as AbbVie's Skyrizi and Johnson and Johnson's Tremfya expand among patients who have failed earlier therapy, displacing older biologics on superior endoscopic and remission outcomes in moderate-to-severe disease.
9. Regional Analysis
Regional demand patterns across the Crohn Disease Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Crohn Disease Market in 2025, accounting for approximately 46% of global revenue, attributed to US premium pricing for ustekinumab, vedolizumab, IL-23p19 inhibitors, and TNF inhibitors and the broad biologic Crohn's prescribing infrastructure. Moreover, IL-23p19 Crohn's adoption with risankizumab is most advanced in the US. In addition, upadacitinib oral Crohn's prescribing is established. Regional dominance is due to this combination of pricing environment and biologic adoption.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Crohn Disease Market through 2034, driven by the growing Crohn's patient population in China, Japan, and South Korea and expanding biologic access through reimbursement. The region is also witnessing IL-23p19 Crohn's adoption growing. Moreover, biosimilar TNF inhibitor access is expanding. The combination of these demand drivers and access expansion positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Crohn Disease Market was valued at USD 11.24 Bn in 2025 and is projected to reach USD 18.67 Bn by 2034, growing at a CAGR of 5.8% over the 2026–2034 forecast period.
The Crohn Disease Market is projected to grow at a CAGR of 5.8% from 2026 to 2034.
North America dominated the Crohn Disease Market in 2025, accounting for approximately 46% of global revenue, attributed to US premium pricing for ustekinumab, vedolizumab, IL-23p19 inhibitors, and TNF inhibitors and the broad biologic Crohn's prescribing infrastructure.
The leading companies in the Crohn Disease Market include AbbVie, Johnson and Johnson, Takeda, Pfizer, Eli Lilly, Bristol-Myers Squibb, Roche, Boehringer Ingelheim, Celltrion, Samsung, UCB, Roivant Sciences.
Risankizumab advance and motivate phase iii 45 and 42 percent clinical remission versus 22 and 19 percent placebo with sequence head-to-head superiority over ustekinumab has established the il-23 selective inhibitor as the superior second-line crohn's disease biologic after tnfi failure.
By drug class, the tumour necrosis factor inhibitor segment dominated the Crohn Disease Market in 2025, as established agents and biosimilars from AbbVie and Johnson and Johnson anchored treatment across the patient population, generating the largest share of Crohn disease revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.